Design Research Development from 2010 to 2026

DSGN Stock  USD 10.27  0.32  3.22%   
Design Therapeutics Research Development yearly trend continues to be very stable with very little volatility. Research Development is likely to drop to about 33.5 M. During the period from 2010 to 2026, Design Therapeutics Research Development quarterly data regression pattern had sample variance of 457 T and median of  1,654,000. View All Fundamentals
 
Research Development  
First Reported
2020-03-31
Previous Quarter
15.7 M
Current Value
14.6 M
Quarterly Volatility
5.2 M
 
Covid
 
Interest Hikes
Check Design Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Design Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 719.7 K, Interest Expense of 5.7 M or Selling General Administrative of 13.3 M, as well as many indicators such as Price To Sales Ratio of 1.1 M, Dividend Yield of 0.0 or PTB Ratio of 1.36. Design financial statements analysis is a perfect complement when working with Design Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Design Stock
Check out the analysis of Design Therapeutics Correlation against competitors.
To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.
Evaluating Design Therapeutics's Research Development across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Design Therapeutics's fundamental strength.

Latest Design Therapeutics' Research Development Growth Pattern

Below is the plot of the Research Development of Design Therapeutics over the last few years. It is Design Therapeutics' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Design Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

Design Research Development Regression Statistics

Arithmetic Mean16,580,478
Geometric Mean5,573,392
Coefficient Of Variation128.93
Mean Deviation18,798,266
Median1,654,000
Standard Deviation21,377,251
Sample Variance457T
Range55.4M
R-Value0.81
Mean Square Error167.6T
R-Squared0.66
Significance0.000081
Slope3,429,269
Total Sum of Squares7311.8T

Design Research Development History

202633.5 M
202551 M
202444.4 M
202357.1 M
202248.6 M
202124.8 M
20206.1 M

About Design Therapeutics Financial Statements

Design Therapeutics investors utilize fundamental indicators, such as Research Development, to predict how Design Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Research Development51 M33.5 M

Pair Trading with Design Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Design Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Design Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Design Stock

  0.78ENGN enGene Holdings CommonPairCorr

Moving against Design Stock

  0.78GNLX Genelux CommonPairCorr
  0.75EVGN EvogenePairCorr
  0.73EDIT Editas MedicinePairCorr
  0.7QSI QuantumSiPairCorr
  0.69LYRA Lyra TherapeuticsPairCorr
The ability to find closely correlated positions to Design Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Design Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Design Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Design Therapeutics to buy it.
The correlation of Design Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Design Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Design Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Design Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Design Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Design Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Design Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Design Therapeutics Stock:
Check out the analysis of Design Therapeutics Correlation against competitors.
To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Will Biotechnology sector continue expanding? Could Design diversify its offerings? Factors like these will boost the valuation of Design Therapeutics. Projected growth potential of Design fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Design Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(1.19)
Revenue Per Share
0.001
Return On Assets
(0.20)
Return On Equity
(0.30)
Investors evaluate Design Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Design Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Design Therapeutics' market price to deviate significantly from intrinsic value.
It's important to distinguish between Design Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Design Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Design Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.